Stockscreener 앱 받기
8.03
2.29%
0.18
시간 외 거래:
7.96
-0.07
-0.87%
Inmune Bio Inc 주식(INMB)의 최신 뉴스
Is INmune Bio (NASDAQ:INMB) A Risky Investment? - Simply Wall St
INmune Delivers Impressive 100% Gain In Just 3 MonthsIs There More Room To Run? - RTTNews
Learn to Evaluate (INMB) using the Charts - Stock Traders Daily
INmune Bio, Inc. to Host Earnings Call - ACCESS Newswire
INmune Bio, Inc. (NASDAQ:INMB) most popular amongst individual investors who own 36% of the shares, institutions hold 28% - Yahoo Finance
INmune Bio, Inc. (NASDAQ:INMB) Receives Consensus Rating of “Buy” from Brokerages - Armenian Reporter
INmune Bio, Inc. (NASDAQ:INMB) Sees Significant Growth in Short Interest - Defense World
INmune Bio, Inc. (NASDAQ:INMB) Receives $21.00 Consensus Price Target from Analysts - Defense World
INmune Bio (NASDAQ:INMB) Stock Price Expected to Rise, Maxim Group Analyst Says - MarketBeat
INmune Bio, Inc. (NASDAQ:INMB) Receives $21.00 Consensus Price Target from Brokerages - Defense World
INmune Bio, Inc. (NASDAQ:INMB) Receives $21.00 Average Price Target from Brokerages - MarketBeat
INmune Bio (NASDAQ:INMB) Stock Price Expected to Rise, Scotiabank Analyst Says - MarketBeat
Raymond James raises INmune Bio stock target to $23 - MSN
(INMB) Investment Report - Stock Traders Daily
INmune Bio price target raised to $23 from $22 at Scotiabank - Yahoo Finance
Raymond James raises INmune Bio stock target to $23 By Investing.com - Investing.com Nigeria
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer - The Manila Times
INmune Bio Inc. Reports Safe Phase 1 Results for INKmune™ in mCRPC, Opens Phase 2 Enrollment - Nasdaq
Inmune Bio’s Strategic Advancements and Promising Clinical Trials Justify Buy Rating - TipRanks
INmune Bio’s CORDStrom shows promise in RDEB treatment By Investing.com - Investing.com Nigeria
Scotiabank raises INmune Bio stock target to $23 on new therapy - MSN
INmune Bio Inc. Discloses New Investor and Webinar PresentationsOn February 10, 2025, INmune Bio Inc. (NASDAQ: INMB) submitted an 8-K form to the Securities and Exchange Commission, revealing that the company had developed an Investor Presentati - Defense World
INmune Bio's CORDStrom shows promise in RDEB treatment - MSN
Market Insight: INmune Bio Inc (INMB)’s Notable Drop, Closing at 9.12 - The Dwinnex
Scotiabank raises INmune Bio stock target to $23 on new therapy By Investing.com - Investing.com South Africa
BLA Submission Planned for CORDStrom in RDEB - MD Magazine
Inmune Bio Secures License Agreement for CORDStrom Data - TipRanks
INmune Bio to Seek Approval of Skin Disorder Treatment in US, UK, Europe -February 10, 2025 at 10:26 am EST - Marketscreener.com
Inmune Bio Completes Phase 2 Trial for CORDStrom - TipRanks
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) - Markets Insider
INmune Bio's CORDStrom shows promise in RDEB treatment By Investing.com - Investing.com South Africa
INmune Bio (INMB) to Submit FDA Biologics License Application Seeking Approval of CORDStrom - StreetInsider.com
Short Interest in INmune Bio, Inc. (NASDAQ:INMB) Expands By 7.0% - MarketBeat
INmune Bio Inc (INMB) shows promising results - US Post News
Trading Day Review: INmune Bio Inc (INMB) Loses Momentum, Closing at 9.31 - The Dwinnex
Analyzing INmune Bio Inc (INMB) After Recent Trading Activity - Knox Daily
INmune Bio, Inc. (NASDAQ:INMB) Short Interest Up 7.0% in January - Defense World
Why INmune Bio Inc (INMB) Is Skyrocketing So Far In 2025 - Insider Monkey
(INMB) Proactive Strategies - Stock Traders Daily
INmune Bio (NASDAQ:INMB) Upgraded to "Strong-Buy" at RODMAN&RENSHAW - MarketBeat
Rodman & Renshaw Begins Coverage on INmune Bio (NASDAQ:INMB) - MarketBeat
0.22%
0.81%
자본화:
|
볼륨(24시간):